<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00168948</url>
  </required_header>
  <id_info>
    <org_study_id>01KA0202-T</org_study_id>
    <secondary_id>01KA0202</secondary_id>
    <nct_id>NCT00168948</nct_id>
  </id_info>
  <brief_title>Intermittent Antimalaria Treatment With SP in African Children</brief_title>
  <official_title>Intermittent Treatment With Sulfadoxine-Pyrimethamine for Malaria Control in Children: A Randomised, Double Blind, and Placebo-Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutscher Akademischer Austausch Dienst</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <brief_summary>
    <textblock>
      - intermittent preventive treatment with SP in children to evaluate efficacy and safety of
      this drug combination in children in northern Ghana
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Sulfadoxine and pyrimethamine have long been used for malaria prevention and treatment.
           In this study, following suggestions of WHO, these drugs are used for intermittent
           treatment.

        -  It will be tested if this approach reduces the number of malaria attacks and ameliorates
           the severity of the disease

        -  It will also be determined if anemia due to malaria, which is prevalent in northern
           Ghana, may be reduced

        -  Moreover, the interaction between red cell polymorphisms such as HbS, HbC,
           alpha-thalassemia and glucose-6-phosphate dehydrogenase deficiency and SP will be
           examined
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2003</start_date>
  <completion_date>August 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy and safety of IPTi with SP</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of IPTi on incidence on malaria attacks</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of IPTi on anemia</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interaction between erythrocyte polymorphisms and SP</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence on parasite multiplicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on child development</measure>
  </secondary_outcome>
  <enrollment>1200</enrollment>
  <condition>Malaria</condition>
  <condition>Anemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfadoxin (12.5) Pyrimethamine (250 mg)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent by parents or guardian

          -  no concomitant serious disease

          -  age &gt;2 months

        Exclusion Criteria:

          -  serious allergy or hypersensitivity to sulfonamides or pyrimethamine

          -  no severe hepatic or renal dysfunction

          -  serious breach of study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>4 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Mockenhaupt, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Charite University-Medicine, Berlin, Germany</affiliation>
  </overall_official>
  <reference>
    <citation>Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, Mshinda H, Alonso P. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet. 2001 May 12;357(9267):1471-7.</citation>
    <PMID>11377597</PMID>
  </reference>
  <reference>
    <citation>Menendez C, Kahigwa E, Hirt R, Vounatsou P, Aponte JJ, Font F, Acosta CJ, Schellenberg DM, Galindo CM, Kimario J, Urassa H, Brabin B, Smith TA, Kitua AY, Tanner M, Alonso PL. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet. 1997 Sep 20;350(9081):844-50.</citation>
    <PMID>9310602</PMID>
  </reference>
  <reference>
    <citation>Massaga JJ, Kitua AY, Lemnge MM, Akida JA, Malle LN, RÃ¸nn AM, Theander TG, Bygbjerg IC. Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial. Lancet. 2003 May 31;361(9372):1853-60.</citation>
    <PMID>12788572</PMID>
  </reference>
  <verification_date>February 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>November 1, 2005</last_update_submitted>
  <last_update_submitted_qc>November 1, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2005</last_update_posted>
  <keyword>Intermittent preventive treatment</keyword>
  <keyword>IPTi</keyword>
  <keyword>Malaria control</keyword>
  <keyword>Ghana</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyrimethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

